Isofol Medical AB (FRA:5IU) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Isofol Medical AB Debt-to-Asset?

Isofol Medical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Isofol Medical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Isofol Medical AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €11.67 Mil. Isofol Medical AB's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Isofol Medical AB Debt-to-Asset Historical Data

The historical data trend for Isofol Medical AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isofol Medical AB Debt-to-Asset Chart

Isofol Medical AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.02

Isofol Medical AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Isofol Medical AB's Debt-to-Asset

For the Biotechnology subindustry, Isofol Medical AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Isofol Medical AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Isofol Medical AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Isofol Medical AB's Debt-to-Asset falls into.

Isofol Medical AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Isofol Medical AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	12.569
	=	0.00

Isofol Medical AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	11.668
	=	0.00

Isofol Medical AB (FRA:5IU) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Isofol Medical AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Isofol Medical AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Isofol Medical AB (FRA:5IU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (FRA:5IU) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ISOFOL:Sweden

Address

Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46

Website

http://www.isofol.se

Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Isofol Medical AB (FRA:5IU) Headlines

No Headlines